Future therapies to overcome the inhibitory immune checkpoints beyond CTLA-4 and PD-1/PD-L1, such as therapies targeting LAG-3, TIM-3 and TIGIT, may be clinically beneficial since immune exhaustion and subsequent tumor escape remains critical for RCC progression. Here, LAG3 is linked to neoplasm.